Medtronic MDT Neuroscience — Net Sales
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Medtronic in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Medtronic’s 10-K, filed June 18, 2026, on SEC EDGAR. View the filing →
Ask your AI about Medtronic's neuroscience — net sales.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Medtronic's neuroscience — net sales?
- Medtronic (MDT) reported neuroscience — net sales of $2.75B in Q1 2026.
- How has Medtronic's neuroscience — net sales changed year-over-year?
- Medtronic's neuroscience — net sales increased by 5.0% year-over-year, from $2.62B to $2.75B.
- What is the long-term trend for Medtronic's neuroscience — net sales?
- Over 5 years (2021 to 2026), Medtronic's neuroscience — net sales has grown at a 4.6% compound annual growth rate (CAGR), from $8.2B to $10.29B.
- What does neuroscience — net sales mean?
- Total revenue earned from selling neuroscience medical products.
- How do you interpret neuroscience — net sales?
- Growth indicates successful product adoption and market share expansion, whereas a decline may signal market saturation or competitive loss.
- How does neuroscience — net sales compare across companies?
- Directly comparable to revenue figures for specific business units in other medical technology companies.